Nektar Therapeutics (LON:0UNL)
68.09
+2.28 (3.46%)
Feb 12, 2026, 5:10 PM GMT
Nektar Therapeutics Employees
Nektar Therapeutics had 61 employees as of December 31, 2024. The number of employees decreased by 76 or -55.47% compared to the previous year.
Employees
61
Change (1Y)
-76
Growth (1Y)
-55.47%
Revenue / Employee
763.45K GBP
Profits / Employee
-1.47M GBP
Market Cap
1.06B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 61 | -76 | -55.47% |
| Dec 31, 2023 | 137 | -79 | -36.57% |
| Dec 31, 2022 | 216 | -524 | -70.81% |
| Dec 31, 2021 | 740 | 22 | 3.06% |
| Dec 31, 2020 | 718 | -5 | -0.69% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AstraZeneca | 94,300 |
| GSK plc | 68,629 |
| Haleon | 24,561 |
| Smith & Nephew | 17,000 |
| Spire Healthcare Group | 15,703 |
| CVS Group | 8,850 |
| Advanced Medical Solutions Group | 1,500 |
| Oxford Nanopore Technologies | 1,325 |
Nektar Therapeutics News
- 13 days ago - Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 17 days ago - Nektar Therapeutics (NKTR) Scheduled for January 28 Meeting - GuruFocus
- 20 days ago - Insider Sell: Jonathan Zalevsky Sells Shares of Nektar Therapeutics - GuruFocus
- 21 days ago - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR - PRNewsWire
- 4 weeks ago - Nektar.io Introduces DIRT: Materials Management for the Construction Industry - Newsfile Corp
- 5 weeks ago - Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics - Nasdaq
- 5 weeks ago - 5 Small Drug Stocks to Buy as Industry Recovery Picks Up - Nasdaq
- 5 weeks ago - Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead - The Motley Fool